… We used an alpha level for statistical significance of p ≤ 0.05 and calculated number
needed to treat/number needed to harm (NNT/NNH) by applying the pooled estimate of relative …

… pravastatin decreased the risk of nonfatal symptomatic MI from 4.3% in the placebo
group to 3.4%, a relatively small reduction in absolute risk (0.9%) and not statistically …

OBJECTIVE: The clinical benefit and cost-effectiveness of self-monitoring of blood glucose (SMBG)
in adults with type 2 diabetes not using insulin has been questioned. The objective of …

Background: Dentists are regular prescribers of opioid analgesic medications; however,
there are few published data on their prescribing practices for children. The aim of this study …

… Allen and McLean-Veysey suggest that pantoprazole and other proton pump inhibitors
are not significantly different from each other on the basis of the observation that the point esti…

All Canadian citizens are eligible for health care services, including hospital care and physician
services, under the Canada Health Act. I Public funding accounts for approximately 69% …

A perceived gap exists in how well Canadian health technology assessment (HTA) producers
are supporting the use of their HTAs by decision-makers. The authors propose that the …

OBJECTIVE: To examine changes in prescribing patterns for topical corticosteroid products
dispensed to elderly patients in Nova Scotia, Canada, after all but 2 combination topical …

… The number of prescriptions for topical corticosteroids per physician profiled was 44.0 in
2000/2001 and 42.8 in 2001/2002 (p= NS) and the expenditures per physician profiled were …

1. Cotter J, Wooltorton E. New restrictions on celecoxib (Celebrex) use and the withdrawal
of valdecoxib (Bextra). CMAJ 2005; 172 (10): 1299. 2. Mukherjee D, Nissen SE, Topol EJ. …